InnoCare Regains Rights to Orelabrutinib as Biogen Terminates Licensing Agreement
Beijing InnoCare Pharma Tech Co., (HKG: 9969), a China-based biotech focusing on cancer and autoimmune...
AIM Vaccine Gains Approvals for COVID-19 mRNA Vaccine Trials in Pakistan
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving separate approvals in Pakistan to...
Innovent Biologics Initiates Phase III CLEAR Study for Picankibart in Psoriasis
China-based Innovent Biologics (HKG: 1801) has announced the first subject dosing in the Phase III...
Frontera Therapeutics Initiates FT-002 Clinical Study for X-Linked Retinitis Pigmentosa
Sino-US gene therapy specialist Frontera Therapeutics has announced the first patient dosing in a clinical...
Kanghong’s KH617 Receives Orphan Drug Designation for Glioblastoma
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving an Orphan Drug...
Luye Pharma’s BA2101 Begins Phase I Clinical Trial for Allergic Diseases
China-based Luye Pharma Group (HKG: 2186) has announced the first subject dosing in a Phase...
CDE Accepts Clinical Trial Filing for Ranok’s First-in-Class BRD4 Degradation Drug RNK05047
The Center for Drug Evaluation (CDE) website indicates that a clinical trial filing for RNK05047,...
Junshi Biosciences and Coherus Report Positive JUPITER-02 Trial Results for NPC Treatment
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) and its US partner Coherus BioSciences...
Eyenovia Partners with Formosa Pharmaceuticals for Ophthalmic Therapeutics
US-based Eyenovia Inc., (NASDAQ: EYEN) has announced a strategic development and collaboration agreement with Taiwan-based...
Brii Biosciences Publishes Positive Phase II Results for HBV Treatment
China’s Brii Biosciences (HKG: 2137) has announced the publication of interim results from a Phase...
Hengrui Pharmaceuticals Gains NMPA Approval for SHR-A1921 Clinical Study
Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving the go-ahead from the National Medical Products...
Grand Pharma Completes First Atrial Fibrillation Treatment with HeartLight X3
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the successful completion of the first...
Zelgen’s ZG2001 and ZG0895 Clinical Trials Approved by NMPA
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that separate clinical trial filings for...
Innovent Biologics Initiates Phase II Study for IBI311 in Thyroid-Associated Ophthalmopathy
China-based Innovent Biologics Inc., (HKG: 1801) has announced the first patient dosing in a Phase...
Hygea Medtech Secures Series D Funding for Oncology Device Expansion
Hygea Medical Technology Co., Ltd, a leading minimally invasive device maker for oncology indications based...
CTI Acquires Vectoring Pharmatech to Expand Pharmacy CMC Research
China-based Centre Testing International Group Co., Ltd (CTI), a leading third-party testing and qualification services...
Shenzhen United Family Hospital Partners with GBA Medical Delegation
Shenzhen United Family Hospital has struck a partnership with a medical delegation from the Guangdong-Hong...
Vincentage Raises RMB 100 Million for Innovative Drug Development
Suzhou-based new drug developer Vincentage has reportedly raised close to RMB 100 million (USD 14.6...
Sequanta and Grandomics Collaborate on Ultra-High Throughput Sequencing Lab
Sequanta Technologies, a multi-omics research and clinical service provider based in Shanghai, and Grandomics Biosciences...
Luzhu Biotech Files for IPO in Hong Kong, Sponsored by CICC
Beijing Luzhu Biotechnology Co., Ltd, a leading human vaccine and therapeutic biologics maker, has made...